Shinpoong Pharmaceutical's primary business objectives are the manufacturing and sale of finished pharmaceuticals and active pharmaceutical ingredients (APIs). It exports products and raw materials to approximately 50 countries, including its overseas subsidiaries. The company focuses on the sales of prescription drugs, with key products such as Roxfen tablets (pain reliever and anti-inflammatory) and Hyal injections (arthritis treatment), as well as antibiotics and cardiovascular products, primarily targeting hospitals and clinics.

Pyramax is an anti-malarial drug that has been registered with EMA in cooperation with MMV. It will be a milestone in the development history of anti-malarial drugs, including the advantages of excellent effects and dosing methods.

Public

Pharma